Study of proteins modulating gliosis in cerebrospinal fluid in neurodegenerative diseases

Study of proteins modulating gliosis in cerebrospinal fluid in neurodegenerative diseases - Study of proteins modulating gliosis in neurodegenerative diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030060

Enrollment

Registered

2017-11-21

Start date

2017-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis (ALS)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Sporadic ALS ALS patients diagnosed as "clinically probable laboratory supported", "clinically probable" or "clinically definite" with El Escorial revised diagnostic criteria (WFN) 2. SOD1-linked ALS ALS patients with SOD1 mutation 3. Control other neurological diseases

Exclusion criteria

Exclusion criteria: Patients with a history of intrathecal infection Patients with a history of intrathecal drug administration Patients with a history of spine or spinal cord surgery

Design outcomes

Primary

Measure	Time frame
Quantification of gliosis-moderating proteins in CSF from ALS patients using enzyme-linked immunosorbent assay (ELISA)	—

Countries

Japan

Contacts

Public ContactTomomi Shijo

Tohoku University Graduate School of Medicine Department of Neurology

shijo-t@med.tohoku.ac.jp022-717-7189

Outcome results